Xencor(XNCR)
PASADENA, CA
BiotechnologyFocus: Antibody Discovery
Xencor is a life sciences company focused on Antibody Discovery.
OncologyImmunology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Abiraterone
Castration-Sensitive Prostate CarcinomaClinical Trials (1)
NCT05733351Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Phase 1XmAb13676
B-cell Non-Hodgkins LymphomaClinical Trials (1)
NCT02924402Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Phase 1XmAb541
Ovarian CancerClinical Trials (1)
NCT06276491Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Phase 1XmAb5574
Chronic Lymphocytic LeukemiaClinical Trials (1)
NCT01161511Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
Phase 1XmAb27564
PsoriasisClinical Trials (1)
NCT06005792Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
Phase 1XmAb18087
Neuroendocrine TumorClinical Trials (1)
NCT03411915A Study of XmAb®18087 in Subjects With NET and GIST
Phase 1XmAb27564
Safety in Healthy VolunteersClinical Trials (1)
NCT04857866Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers
Phase 1XmAb22841
Metastatic MelanomaClinical Trials (1)
NCT05695898XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
Phase 1Phase 1
Clinical Trials (1)
NCT05585034Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1XmAb5871
Healthy VolunteersXmAb®23104
Melanoma (Excluding Uveal Melanoma)Clinical Trials (1)
NCT03752398A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Phase 1XmAb7195
Allergic RhinitisClinical Trials (1)
NCT02148744Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
Phase 1XmAb2513
Hodgkin LymphomaClinical Trials (1)
NCT00606645Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Phase 1XmAb662
Solid TumorsClinical Trials (1)
NCT05996445A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1XmAb®22841
MelanomaClinical Trials (1)
NCT03849469A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Phase 1XmAb20717
MelanomaClinical Trials (1)
NCT03517488A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT03445663Study Evaluating AMG 424 in Subjects With Multiple Myeloma
Phase 1XmAb14045
Acute Myelogenous LeukemiaClinical Trials (1)
NCT02730312PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Phase 1XmAb13676
HealthyClinical Trials (1)
NCT07284797A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)
Phase 1Phase 1
Clinical Trials (1)
NCT05433142Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Phase 1XmAb7195
Healthy VolunteersClinical Trials (1)
NCT02881853Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195
Phase 1XmAb13676
Rheumatoid ArthritisClinical Trials (1)
NCT07230353A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis
Phase 1XmAb18087
Merkel Cell CarcinomaClinical Trials (1)
NCT04590781Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Phase 1/2XmAb942
Ulcerative Colitis (UC)Clinical Trials (1)
NCT06619990Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Phase 1/2Vudalimab + Carboplatin + Pemetrexed
Nonsquamous Non-small Cell Lung CancerClinical Trials (1)
NCT06173505Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Phase 1/2Regorafenib
Colorectal CancerClinical Trials (1)
NCT05900648Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Phase 2Plamotamab
Diffuse Large-cell B-cell LymphomaClinical Trials (1)
NCT05328102Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Phase 2vudalimab
Ovarian CancerClinical Trials (1)
NCT05032040A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Phase 2vudalimab + carboplatin + cabazitaxel
Metastatic Castration-Resistant Prostate CancerClinical Trials (1)
NCT05005728XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 2XmAb5871
IgG4-RDClinical Trials (1)
NCT02725476Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
Phase 2XmAb5871
Systemic Lupus ErythematosusClinical Trials (1)
NCT02725515A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
Phase 2XmAb20717
Biliary Tract CancerClinical Trials (1)
NCT05297903XmAb20717 in Advanced Biliary Tract Cancers
Phase 2XmAb23104
SarcomaClinical Trials (1)
NCT05879185A Study of XmAb23104 in People With Sarcoma
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 32 clinical trials
Top TAs: Oncology
SEC Filings: 2 available
Financials (FY2025)
Revenue
$175M6%
R&D Spend
$254M(145%)27%
Net Income
-$133MCash
$41MHiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles